Study of QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Trial Profile

Study of QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs QR 313 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2016 New trial record
    • 14 Nov 2016 According to a ProQR media release, company plans to start this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top